POST-TEST

Meet The Professor: Optimizing the Clinical Management of Hodgkin and Non-Hodgkin Lymphomas — Part 6 of an 8-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **In the Phase III CHRONOS-3 trial, what was the progression-free survival (PFS) benefit as measured by hazard ratio observed with the addition of copanlisib to rituximab for patients with relapsed/refractory indolent non-Hodgkin lymphoma?**
   a. No PFS benefit, HR = 1
   b. Nonsignificant improvement in median PFS, HR = 0.89
   c. Significant improvement in median PFS, HR = 0.52

2. **Which of the following observations was reported in the pivotal Phase III POLARIX trial comparing polatuzumab vedotin/R-CHP to R-CHOP for patients with previously untreated diffuse large B-cell lymphoma (DLBCL)?**
   a. The primary endpoint of prolonged PFS was met
   b. The primary endpoint of prolonged PFS was not met
   c. An excess of severe toxicity leading to deaths was observed with polatuzumab vedotin/R-CHP

3. **On the basis of the pivotal LOTIS-2 study, the CD19-directed antibody and alkylating agent conjugate loncastuximab tesirine was approved for which patients with DLBCL?**
   a. Patients with newly diagnosed DLBCL
   b. Patients who have received at least 1 prior systemic regimen
   c. Patients who have received at least 2 prior systemic regimens
   d. Patients who have received at least 4 prior systemic regimens

4. **Which of the following treatment-related adverse events was most common with mosunetuzumab in Phase I/II investigation of mosunetuzumab monotherapy for patients with relapsed/refractory (R/R) follicular lymphoma who have received at least 2 prior lines of therapy?**
   a. Hypokalemia
   b. Headache
   c. Cough
   d. Cytokine release syndrome

5. **Which of the following subgroups of patients with R/R DLBCL experienced the best response rates with loncastuximab tesirine in combination with ibrutinib in the Phase II LOTIS-3 study?**
   a. Non-germinal center B-cell like (GCB) DLBCL
   b. GCB DLBCL
   c. All-comers